WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462266
CAS#: 190648-49-8
Description: Cipemastat is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent.
Hodoodo Cat#: H462266
Name: Cipemastat
CAS#: 190648-49-8
Chemical Formula: C22H36N4O5
Exact Mass: 436.27
Molecular Weight: 436.553
Elemental Analysis: C, 60.53; H, 8.31; N, 12.83; O, 18.32
Synonym: Cipemastat; Ro 32-3555; Ro 32 3555; Ro 323555
IUPAC/Chemical Name: (2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-((3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl)butanamide
InChi Key: GFUITADOEPNRML-SJORKVTESA-N
InChi Code: InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
SMILES Code: O=C(N1C[C@H](C(NO)=O)[C@H](C(N2CCCCC2)=O)CC3CCCC3)C(C)(C)N(C)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 436.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ordonez AA, Pokkali S, Sanchez-Bautista J, Klunk MH, Urbanowski ME, Kübler A, Bishai WR, Elkington PT, Jain SK. Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology. J Infect Dis. 2019 Jan 29;219(4):633-636. doi: 10.1093/infdis/jiy373. PMID: 29920600; PMCID: PMC6601699.
2: Urbanowski ME, Ihms EA, Bigelow K, Kübler A, Elkington PT, Bishai WR. Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction. J Infect Dis. 2018 Jun 5;218(1):53-63. doi: 10.1093/infdis/jiy127. PMID: 29554286; PMCID: PMC5989619.
3: Jayatilaka H, Umanzor FG, Shah V, Meirson T, Russo G, Starich B, Tyle P, Lee JSH, Khatau S, Gil-Henn H, Wirtz D. Tumor cell density regulates matrix metalloproteinases for enhanced migration. Oncotarget. 2018 Aug 24;9(66):32556-32569. doi: 10.18632/oncotarget.25863. PMID: 30220965; PMCID: PMC6135685.
4: Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. doi: 10.1128/IAI.00073-14. Epub 2014 Feb 3. Erratum in: Infect Immun. 2014 Oct;82(10):4435. PMID: 24491581; PMCID: PMC3993388.
5: Yin Z, Sada AA, Reslan OM, Narula N, Khalil RA. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E55-70. doi: 10.1152/ajpendo.00553.2011. Epub 2012 Apr 10. PMID: 22496348; PMCID: PMC3404560.